#AANAM – Gene Therapy Treats CMTX Even After Disease Onsest, Mouse Study Suggests

#AANAM – Gene Therapy Treats CMTX Even After Disease Onsest, Mouse Study Suggests

Gene therapy can be of benefit even after neuropathy has begun, research in a mouse model of X-linked Charcot-Marie-Tooth disease (CMTX) found.

The study, “Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X,” was presented by Kleopas Kleopa at the 2019 American Academy of Neurology (AAN) annual meeting that recently concluded in Philadelphia.

CMTX is caused by mutations in the gene GJB1, which encodes for a protein called connexin-32 (Cx32). These mutations cause the loss of a working protein, leading to manifestation of the disease.

An intuitive way to treat CMTX would be to “add” a functional (that is, non-mutated) version of this gene into patients’ cells. Viral gene therapy, which uses a modified virus to deliver a gene to particular kinds of cells, attempts to do just that.

The study’s researchers had previously used this strategy to show therapeutic benefits in a mouse model of CMTX. They constructed a virus to deliver a working version of the gene to Schwann cells of these mice. Of note, Schwann cells produce myelin, the protective coating around neurons that helps them function and that isn’t produced correctly in CMTX.

CMTX mice typically start developing disease features at three months of age. So in the previous study, the researchers gave them with the gene therapy just before this timepoint, or at age 2 months. But in the real world, a disease — especially a rare disease — might not be diagnosed before its symptoms are evident.

So, the research team wondered, might this gene therapy still be of benefit after the start of disease?

The team injected, via the spinal canal, one group of CMTX mice with their Cx32-encoding virus and another with a mock virus not coding for this protein (a control group). These injections were given to the mice at 6 months old, well after disease onset. The researchers then looked at the mice’s behavior and for changes in the their nervous systems at 8 and 10 months old.

Analysis confirmed that mice given the gene therapy expressed the Cx32 protein in the correct cells and body tissues. Treated mice also had less inflammation and more myelin (less abnormally myelinated fibers) than controls, and treated mice had lower levels of neurofilament light (Nfl) — a clinically relevant biomarker of nerve damage — in their blood.

Treated mice also showed improved motor skills and better sciatic nerve conduction velocity, which essentially means that  their neurons “worked better” than those of controls with natural disease progression.

These data suggest that gene therapy can be beneficial in CMTX even if the therapy isn’t started until after the disease has started to progress, the study siad.

“Intrathecal [injection into the spinal canal] gene delivery after the onset of peripheral neuropathy still offers a significant therapeutic benefit in this disease model providing a proof of principle for treating patients with CMT1X,” the researchers concluded.

 

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • CMT awareness month
  • eyes
  • Schwann cells, Ep400
  • Passage Bio

7 comments

  1. Susan Crawley says:

    This research sounds wonderful, I doubt that it would help me at my age of 70 years old, I was diagnosed probably around 2012, I had all kinds of nerve biopsy test and had developed Sjogrens Syndrome maybe around the same time, I can’t walk without help from a walker, or a riding scooter that I purchased in July 2018, in 2014 I started falling backwards with no balance at all! I have pulled both rotator cuff in both arms, I am not able to have shoulder replacement because of my health and weak muscles in both arms and top part of my leg muscles! I can’t go out of my house without a wheelchair and can’t walk out of the car or do anything for myself when it comes to balancing, for example can’t get in and out of the shower without assistance or can’t cook, wash dishes or reach above my head! So this would be a wonderful findings concerning CMT Neuropathy and hope in the future it will help young people that has this!

    • Dave Merritt says:

      Hi Bessie. My daughter was diagnosed two years ago. She’s 15 now. We’ve been going to the CMT Center of Excellence in Mass General in Boston. Her doctor there is going to a conference in Italy next week to learn more potential treatment options. If you wanted to create a little network to share this type of information, please let me know. I’ll send you my email address.

  2. Eileen Ball says:

    I would definitely be ready to be a participant in a human trial as I still lose my balance even with wearing my braces. I do not want to be in a wheelchair and would like to keep walking and I think this treatment would be a blessing for me and others who struggle with CMT. Help us if you can!!!

Leave a Comment

Your email address will not be published. Required fields are marked *